Article

FDA Updates HIV Drug Label to Include Dosing for Pregnant Patients

The FDA updated the labeling for rilipivirine (Edurant) for the treatment of HIV-positive pregnant patients who were on stable treatment prior to conception and who are virologically suppressed.

Today, the FDA updated the labeling for rilipivirine (Edurant) for the treatment of HIV-positive pregnant patients who were on stable treatment prior to conception and who are virologically suppressed, according to an agency update.

The label recommends that these patients take one 25-mg tablet once per day with a meal. The FDA noted that lower exposures of rilipivirine were observed during pregnancy, meaning that viral load should be monitored closely.

The update also includes clinical considerations dealing with dose adjustments that are necessary during pregnancy and post-partum.

For more information, visit SpecialtyPharmacyTimes.com.

Related Videos
Image Credit: © Birdland - stock.adobe.com
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
Pharmacist assists senior woman in buying medicine in pharmacy - Image credit: Drazen | stock.adobe.com
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
Pharmacists working in a pharmacy -- Image credit: Drazen | stock.adobe.com
Image Credit: © Krakenimages.com - stock.adobe.com
Young female pharmacist working in her large pharmacy. Placing medications, taking inventory. Lifestyle - Image credit: lubero | stock.adobe.com
Pharmacist helping patient -- Image credit: Clayton D/peopleimages.com | stock.adobe.com
Pharmacist and a patient -- Image credit: Zamrznuti tonovi | stock.adobe.com